As more pricing pressure builds, PBMS have maneuvered toward more transparent pricing models to appease regulators and customers despite IQVIA data proving that net brand price growth didn’t match the CPI for the first time in years. Of all PBM services, Medicare Part D and Medicaid have realized significant growth. Sharp increases in specialty drug prices should pay dividends to the greater specialty pharmacy market. Specialty drug spend has materially grown in retail and mail-order channels.
The report also features relevant precedent transactions that have occurred in the recent past.